Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 3, 1998, Pages 799-805

  Anastasopoulos, Frank ^a   Leung, Randal ^a   Kladis, Athena ^a   James, Gail M ^a   Briscoe, Todd A ^a   Gorski, Thaddeus P ^a   Campbell, Duncan J ^a  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(1 BENZYL 3 HYDROXYAMINO 3 OXOPROPYL)AMINO] 2 (4 HYDROXY 3 IODOBENZYL) 4 OXOBUTANOIC ACID; ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSINOGEN; BRADYKININ DERIVATIVE; CAPTOPRIL; CREATININE; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; N (2 MERCAPTOMETHYL 3 PHENYLBUTYRYL)ALANINE; RENIN; SODIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HYPERTENSION; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; MALE; NONHUMAN; POTASSIUM EXCRETION; PRIORITY JOURNAL; RAT; SODIUM EXCRETION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CAPTOPRIL; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY; MALE; NEPRILYSIN; PROPIONATES; RATS; RATS, SPRAGUE-DAWLEY; RENIN; SULFHYDRYL COMPOUNDS;

EID: 0031932306     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Boomsma F, De Bruyn JHB, Derkx FHM and Schalekamp MADH (1981) Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response. Clin Sci 60:491-498.
2. Campbell DJ, Kladis A and Duncan A-M (1993a) Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 21:155-165.
3. Campbell DJ, Kladis A and Duncan A-M (1993b) Nephrectomy, converting enzyme inhibition and angiotensin peptides. Hypertension 22:513-522.
4. Campbell DJ, Kladis A and Duncan A-M (1994) Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23:439-449.
5. Campbell DJ, Lawrence AC, Towrie A, Kladis A and Valentijn AJ (1991) Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 18:763-773.
6. Campbell DJ, Lawrence AC, Kladis A and Duncan A-M (1995) Strategies for measurement of angiotensin and bradykinin peptides and their metabolites in central nervous system and other tissues, in Methods in Neurosciences, vol. 23: Peptidases and Neuropeptide Processing (Smith AI, ed) pp 328-343, Academic Press, Orlando.
7. Cody RJ, Schaer GL, Covit AB, Pondofino K and Williams G (1982) Captopril kinetics in chronic congestive heart failure. Clin Pharmacol Ther 32:721-726.
8. Crozier IG, Ikram H and Nicholls MG (1993) Angiotensin-converting enzyme inhibitors in the treatment of heart failure, in The Renin-Angiotensin System (Robertson JIS and Nicholls MG, eds) pp 93.1-93.21, Gower Medical Publishing, London.
9. Cushman DW, Cheung HS, Sabo EF and Ondetti MA (1977) Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16:5484-5491.
10. Drummer OH and Jarrott B (1986) The disposition and metabolism of captopril. Med Res Rev 6:75-97.
11. Erdos EG (1990) Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension 16:363-370.
12. Flynn GA, Beight DW, Mehdi S, Koehl JR, Giroux EL, French JF, Hake PW and Dage RC (1993) Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J Med Chem 36:2420-2423.
13. Flynn GA, French JF and Dage RC (1995) Dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase: design and therapeutic rationale, in Hypertension: Pathophysiology, Diagnosis, and Management (Laragh JH and Brenner BM, eds) pp 3099-3114, Raven Press, Ltd., New York.
14. Fournié-Zaluski M-C, Coric P, Turcaud S, Rousselet N, Gonzalez W, Barbe B, Pham I, Jullian N, Michel J-B and Roques BP (1994a) New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: Rational design, bioavailability, and pharmacological responses in experimental hypertension. J Med Chem 37:1070-1083.
15. Fournié-Zaluski MC, Gonzalez W, Turcaud S, Pham I, Roques BP and Michel JB (1994b) Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: A potential therapeutic approach in hypertension. Proc Natl Acad Sci USA 91:4072-4076.
16. 125I]RB104, a potent inhibitor of neutral endopeptidase 24.11, and its use in detecting nanogram quantities of the enzyme by "inhibitor gel electrophoresis." Proc Natl Acad Sci USA 89:6388-6392.
17. Friedman M (1977) Chemical basis of pharmacological and therapeutic actions of penicillamine. Adv Exp Med Biol 86B:649-673.
18. Gonzalez W, Beslot F, Laboulandine I, Fournié-Zaluski MC, Roques BP and Michel JB (1996a) Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction. J Pharmacol Exp Ther 278:573-581.
19. Gonzalez W, Fournié-Zaluski MC, Turcaud S, Roques BP and Michel JB (1996b) Pharmacology of S21402 (RB105): A dual inhibitor of neutral endopeptidase and angiotensin converting enzyme. Cardiovasc Drug Rev 14:166-184.
20. Gros C, No 137 l N, Souque A, Schwartz J-C, Danvy D, Plaquevent J-C, Duhamel L, Duhamel P, Lecomte J-M and Bralet J (1991) Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): Rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 88:4210-4214.
21. Hansson L, Dahlöf B, Himmelmann A and Svensson A (1993) Angiotensin-converting enzyme inhibitors in the treatment of essential hypertension, in The Renin-Angiotensin System (Robertson JIS and Nicholls MG, eds) pp 91.1-91.24, Gower Medical Publishing, London.
22. Hui KY, Holtzman EJ, Quinones MA, Hollenberg NK and Haber E (1988) Design of rat renin inhibitory peptides. J Med Chem 31:1679-1686.
23. Kirk JE and Wilkins MR (1996) Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat. Br J Pharmacol 119:943-948.
24. Mannervik B (1982) Mercaptans, in Metabolic Basis of Detoxication: Metabolism of Functional Groups (Jakoby WB, Bend JR and Caldwell J, eds) pp 185-206, Academic Press, New York.
25. Marguilies KB, Perrella MA, McKinley LJ and Burnett JC Jr (1991) Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 88:1636-1642.
26. Ondetti MA, Rubin B and Cushman DW (1977) Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196:441-444.
27. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM and Kosoglou T (1996a) Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci 91:283-291.
28. Rademaker MT, Fitzpatrick MA, Charles CJ, Richards AM, Nicholls MG, Espiner EA and Sybertz E (1996b) Comparison of chronic neutral endopeptidase inhibition and furosemide in an ovine model of heart failure. J Cardiovasc Pharmacol 27:439-446.
29. Richards M, Espiner E, Frampton C, Ikram H, Yandle T, Sopwith M and Cussans N (1990) Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension 16:269-276.
30. Roques BP, Noble F, Daugé V, Fournié-Zaluski M-C and Beaumont A (1993) Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87-146.
31. Schmitt F, Martinez F, Ikeni A, Savoiu C, Natov S, Laborde K, Lacour B, Grünfeld J-P and Hannedouche T (1994) Acute renal effects of neutral endopeptidase inhibition in humans. Am J Physiol 267:F20-F27.
32. Trippodo NC, Panchal BC and Fox M (1995a) Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J Pharmacol Exp Ther 272:619-627.
33. Trippodo NC, Robl JA, Asaad MM, Bird JE, Panchal BC, Schaeffer TR, Fox M, Giancarli MR and Cheung HS (1995b) Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 275:745-752.
34. Vera WG, Fournié-Zaluski M-C, Pham I, Laboulandine I, Roques B-P and Michel J-B (1995) Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J Pharmacol Exp Ther 272:343-351.
35. Willenbrock R, Scheuermann M, Höhnel K, Luft FC and Dietz R (1996) Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt. Hypertension 27:1259-1266.
36. Yandle T, Richards M, Smith M, Charles C, Livesey J and Espiner E (1992) Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin Chem 38:1785-1791.